60 Degrees Pharmaceuticals Inc. (SXTP) Reports Q2 Loss, Tops Revenue Estimates
Zacks60 Degrees Pharmaceuticals Inc. (SXTP) delivered earnings and revenue surprises of -6.82% and 13.64%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?